BioGaia Takes Full Control of U.S. Distributor Nutraceutics

The latest update is out from BioGaia AB ( ($SE:BIOG.B) ).

BioGaia has moved to take full control of its U.S. distribution by exercising an option to buy the remaining 20 percent of Nutraceutics, parent of BioGaia USA, its exclusive distributor in the American market. The deal, effective April 1, 2026 for 6.4 million dollars, will make Nutraceutics and BioGaia USA wholly owned subsidiaries, consolidating the group’s U.S. operations without any planned management changes.

The transaction completes a two-step acquisition process that began with an 80 percent stake purchase in 2021, underscoring BioGaia’s strategy to tighten control over its key growth market. Full ownership of the U.S. distributor is expected to streamline decision-making and branding in the United States, reinforcing the company’s direct presence in one of the world’s largest probiotic and gut health markets.

The most recent analyst rating on ($SE:BIOG.B) stock is a Hold with a SEK109.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.

More about BioGaia AB

BioGaia AB is a Swedish probiotic company that has focused on microbiome research for more than 35 years. It develops, markets, and sells probiotic products targeting gut, immune, and oral health, distributing through partners and its own channels in over 100 markets, and its class B shares trade on Nasdaq Stockholm’s Mid Cap segment.

Average Trading Volume: 257,594

Technical Sentiment Signal: Strong Buy

Current Market Cap: SEK11.73B

Learn more about BIOG.B stock on TipRanks’ Stock Analysis page.